Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
153 hedge funds and large institutions have $144M invested in Clovis Oncology, Inc. in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 38 reducing their positions, and 24 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 38
33% more call options, than puts
Call options by funds: $5.25M | Put options by funds: $3.96M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
1% less funds holding
Funds holding: 154 → 153 (-1)
27% less capital invested
Capital invested by funds: $198M → $144M (-$54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.39M |
| 3 |
HF
HRT Financial
New York
|
+$1.8M |
| 4 |
Renaissance Technologies
New York
|
+$1.67M |
| 5 |
Two Sigma Investments
New York
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$26.5M |
| 2 |
Rafferty Asset Management
New York
|
-$3.61M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.88M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.15M |
| 5 |
Citigroup
New York
|
-$1.73M |
CLVS Hedge Fund Activity: Q1 2022 in Review
153 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2022, worth a combined $144M — down 27% from $198M a quarter earlier.
Fund positioning in CLVS was balanced in Q1 2022: 24 funds opened new positions, 24 closed out, 56 added to existing stakes and 38 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.96M. The largest seller was State Street, cutting an estimated $26.5M.
- 153 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2022, down from 154 in Q4 2021.
- Funds reported $144M of Clovis Oncology, Inc. stock for Q1 2022, down 27% quarter-over-quarter.
- 24 funds opened new Clovis Oncology, Inc. positions in Q1 2022 and 24 closed out, a net change of 0 holders.
- The largest Clovis Oncology, Inc. buyer in Q1 2022 was Millennium Management, an estimated $4.96M added.
- The largest Clovis Oncology, Inc. seller in Q1 2022 was State Street, an estimated $26.5M sold.
Based on aggregated 13F filings for Q1 2022.